Loading
Small Cell Carcinoma of Lung / Atezolizumab, Etoposide, Carboplatin, Tarlatamab · Phase 2 Trial
ClinicalTrials.gov · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 trial registration (NCT06830694) evaluating tarlatamab combined with etoposide, carboplatin and atezolizumab in transformed small cell lung cancer arising from EGFR-mutant adenocarcinoma after TKI resistance. No results are posted in this registry record; the trial is currently recruiting and planned to assess progression-free survival over 6 months in an estimated 50 participants.
Phase 2, Interventional, Single Group, Open label, Treatment purpose. Small Cell Carcinoma of Lung; age from 19 Years. Intervention: Single arm. n = 50. 1 site: South Korea.
Primary outcome: progression-free survival up to 6 months Target population: patients with SCLC transformed from EGFR-mutant adenocarcinoma after EGFR TKI treatment Planned enrollment: 50 participants (estimated)
This is a registry record with no posted results; efficacy and safety data are not yet available Only the primary outcome measure (PFS at 6 months) is specified; secondary endpoints, safety profiling, and overall survival are not detailed in this registry record
This trial addresses an unmet clinical need in a rare subgroup of SCLC patients (transformed from adenocarcinoma). Clinicians should note that results are not yet available; this represents an exploratory combination strategy combining a novel bispecific T-cell engager (tarlatamab/DLL3-targeting) with standard chemotherapy and immunotherapy.
This is a Phase 2 trial registration with no posted results; it describes a planned study in a rare population (transformed SCLC) using a combination of experimental and standard agents, based on mechanistic rationale and early-phase data from other cohorts.
As stated by the source record.
Quoted from the source exactly as published.
This trial addresses an unmet clinical need in a rare subgroup of SCLC patients (transformed from adenocarcinoma). Clinicians should note that results are not yet available; this represents an exploratory combination strategy combining a novel bispecific T-cell engager (tarlatamab/DLL3-targeting) with standard chemotherapy and immunotherapy.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Registry record from ClinicalTrials.gov (NCT06830694). This is a study registration, not published results. Lead sponsor: Sehhoon Park. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 50 participants (ESTIMATED). Conditions: Small Cell Carcinoma of Lung. Interventions: DRUG: Atezolizumab, Etoposide, Carboplatin, Tarlatamab. Primary outcome measures: Progression-free survival(PFS) , Up to 6months. Brief summary: The primary treatment option for non-small cell lung cancer (NSCLC) adenocarcinoma (ADC) with activating epidermal growth factor receptor (EGFR) mutation is EGFR tyrosine kinase inhibitor (TKI). After a certain period of treatment with EGFR TKI, acquired resistance emerges most frequently with a secondary mutation, p.T790M (36-50%), followed by MET amplification (10-19%). Interestingly, up to 3-5% of patients experience histological transformation into small cell lung cancer (SCLC). As an underlying mechanism, ADC with a predisposed clonally inactivated Rb and p53 mutation and APOBEC mutation signature is known to be associated with SCLC transformation. The transformed SCLC harbors similar morphological and immunohistochemical (IHC) characteristics as those observed in de novo SCLC, including high expression of chromogranin and synaptophysin. However, little is known about the clinical outcomes of transformed SCLC, with limited studies arguing that their outcomes are similar to those of de novo SCLC, where the median overall survival is approximately 9 to 10 months after the transformation. As the first line treatment of SCLC, atezolizumab or durvalumab with four cycles of conventional chemotherapy followed by maintenance therapy demonstrated prolonged overall survival (OS) and placed as the standard treatment option. However, median progression-free survival (PFS) of both study was only 5.2 months and 5.1 months, despite the objective response rate showing 60.2% and 79%. This finding suggest further development of maintenance treatment strategy to prolonged longer duration of response to the treatment. In addition to the conventional treatment, Tarlatamab (AMG757), bispecific t-cell engager (BiTE), designed to engage DLL3 on SCLC and CD3 on T-cell has been tested in SCLC. DLL3 is expressed in more than 80% of patients with SCLC, regardless of disease stage and researched for the potential target protein for the antibody based treatment in SCLC. By targeting DLL3 using Tarlatamab, engagement of tumor antigen and CD3 lead to cytotoxic synapse formation, triggering the release of proinflammatory cytokines, perforin, and granzymes from activated T-cells, potentially resulting apoptosis. The first clinical outcome of Tarlatamab was reported from the DeLLphi-300 study, phase 1 dose exploration study, showing confirmed partial response in 23% of the heavily treated SCLC and 37% of the patients showed decrease in tumor burden. Median duration of response was 13.0 months (95% confidential interval CI: 6.2 - 14.9 months), median PFS of 3.7 months and median OS was 13.2 months. In the treatment naïve SCLC, DeLLphi-303 study, phase 1b study combining tarlatamab + PD-L1 inhibitor + carboplatin and etoposide, is ongoing to evaluate the clinical efficacy in the front line setting which include only histologically confirmed extensive disease SCLC population (NCT05361395). Based on previous clinical and pre-clinical outcomes, showing similar disease characteristics between transformed SCLC from the adenocarcinoma who treated with EGFR TKI with de novo SCLC, this study is designed to evaluate the clinical efficacy of tarlatamab with currently standard treatment in transformed SCLC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.